Rekord LOINC: 82905-1
Dostępne tłumaczenie polskie ACTIVE
Tłumaczenie polskie
Komponent
Właściwość
Aspekt czasowy
System
Typ skali
Typ metody
Klasa
Krótka nazwa
Długa nazwa wspólna
Definicja i opis
Szczegóły rekordu LOINC
Informacje podstawowe
| Kod LOINC: |
82905-1
FHIR
|
| Long Common Name: | t(9;22)(q34.1;q11)(ABL1,BCR) fusion transcript/control transcript [Log Number Ratio] in Bone marrow by Molecular genetics method |
| Short Name: | t(9;22)(ABL1,BCR)/control Mar-LnRto |
| Status: | ACTIVE |
| Class Type: | 1 |
Fully Specified Name (FSN)
PL
Tłumaczenie polskie
t(9;22)(q34.1;q11)(ABL1,BCR) transkrypt fuzyjny/transkrypt kontrolny
:
współczynnik logarytmowo-liczbowy
:
punkt w czasie
:
szpik kostny
:
ilościowy
:
genetyka molekularna
EN
Oryginalna wersja angielska
t(9;22)(q34.1;q11)(ABL1,BCR) fusion transcript/control transcript
:
LnRto
:
Pt
:
Bone mar
:
Qn
:
Molgen
Klasyfikacja
| Class: |
PLpatologia molekularna, translokacje
ENMOLPATH.TRNLOC
|
| Consumer Name: | - |
| Order/Observation: | Both |
| Panel Type: | - |
Informacje dodatkowe
| Units Required: | - |
| Example Units: | Log Reduction |
| UCUM Units: | {log_reduction} |
| Version Last Changed: | 2.58 |
Definicja i opis
EN
The level of fusion gene transcript in the test sample is expressed as a log reduction; i.e., log10 of the ratio of chimeric BCR-ABL/normal ABL mRNA transcript seen in individuals with untreated CML (Chronic Myelogenous Leukemia) as compared to the ratio seen in the patient. In Quest's laboratory data, the median of BCR-ABL/ABL Ratio in previously untreated CML patients is 4.1325 in peripheral blood samples (N=120) and 5.09 in bone marrow samples (N=109). Based on the IRIS study (New England Journal of Medicine, 2003, 3349:1423-1432), it is not necessary to know the BCR-ABL:ABL ratio of a patient at baseline to calculate the subsequent change and this calculation should be based on the above-mentioned median. Based on this study, a 3 log of higher reduction by 12 months of therapy is associated with negligible risk of disease progression during the subsequent 12 months with patients are treated with imatinib. The following formula is used for calculating log reduction by Quest Laboratories: LOG10(4.1325)-LOG10 (BCR-ABL:ABL ratio) Unit/Log Reduction. Information from Quest Diagnostics. 2006 12 06.
Powiązane nazwy
diagnostyka molekularna